Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial

Am J Hematol. 2022 Jun 1;97(6):E204-E207. doi: 10.1002/ajh.26537. Epub 2022 Mar 22.

Authors

Giovanni Fernando Torelli¹, Sabina Chiaretti¹, Nadia Peragine¹, Walter Barberi¹, Laura Santodonato², Giuseppina D'Agostino², Elisabetta Abruzzese³, Maria Ilaria Del Principe⁴, Alessandra Mancino⁵, Mabel Matarazzo¹, Mahnaz Shafii Bafti¹, Marco Mancini¹, Monica Messina⁵, Luciano Castiello², Anna Guarini¹, Robin Foà¹

Affiliations

¹ Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, Rome, Italy.
² FaBioCell Cell Factory, Istituto Superiore di Sanità, Rome, Italy.
³ Hematology, Sant'Eugenio Hospital, ASL Roma2, Tor Vergata University, Rome, Italy.
⁴ Hematology, Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
⁵ Data Center, Fondazione GIMEMA Onlus, Rome, Italy.

PMID: 35315128
DOI: 10.1002/ajh.26537

No abstract available

Publication types

Clinical Trial, Phase I
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Hematopoietic Stem Cell Transplantation*
Humans
Killer Cells, Natural
Neoplasm, Residual
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Transplantation, Autologous